TW201137124A - Immunomodulatory compositions - Google Patents

Immunomodulatory compositions Download PDF

Info

Publication number
TW201137124A
TW201137124A TW099113813A TW99113813A TW201137124A TW 201137124 A TW201137124 A TW 201137124A TW 099113813 A TW099113813 A TW 099113813A TW 99113813 A TW99113813 A TW 99113813A TW 201137124 A TW201137124 A TW 201137124A
Authority
TW
Taiwan
Prior art keywords
composition
group
egg yolk
ifn
specific
Prior art date
Application number
TW099113813A
Other languages
Chinese (zh)
Other versions
TWI490336B (en
Inventor
David Chang-Ping Chen
Yi-Shu Chung
Original Assignee
Asia Hepato Gene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asia Hepato Gene Corp filed Critical Asia Hepato Gene Corp
Priority to TW099113813A priority Critical patent/TWI490336B/en
Publication of TW201137124A publication Critical patent/TW201137124A/en
Application granted granted Critical
Publication of TWI490336B publication Critical patent/TWI490336B/en

Links

Abstract

The present invention relates to an immunomodulatory composition comprising a yolk product from eggs laid by female poultry which has been immunized with Helicobacter pylori. The immunomodulatory composition of the invention is effective in modulating an immune response in a subject. In particular, the immunomodulatory composition can promote production of IFN- γ and inhibit production of IL-4 and IL-5 in a subject.

Description

201137124 六、發明說明: 【發明所屬之技術領域】 本發明係關於一種免疫調節之組合物,其可提升個體對抗 病原之免疫反應及降低發炎反應。 ~ 【先前技術】 免疫系統為身體用來保護自己防禦外來的微生物、毒素、 本身的癌細胞、或是來自他人的血液或組織等可能有害物質的 一個防禦系統。免疫系統可分為先天及後天免疫系統。先天免 疫系統(又稱非特異性免疫系統)係作為第一道防禦機制,可 提供立即的保護,相關成員包括天然殺手細胞、巨噬細胞、嗜 中性白血球、嗜酸性白血球等。後天免疫系統(又稱特異性免 疫系統)’則是作為第二道防禦機制,需要時間產生針對特定 抗原之免疫反應,相關成員包括T細胞與B細胞。 後天免疫系統可產生輔助T細胞第1型(Thl)免疫反應 及輔助T細胞第2型(Th2)免疫反應。Thl免疫反應主要是 指細胞調節的免疫反應’其涉及白細胞介素_2 (IL-2)及干擾 素-γ (IFN-γ)之分泌及細胞毒殺T淋巴細胞(CTLs).之活化, 可對抗病毒感染及癌細胞。Th2免疫反應主要是指體液免疫反 應,其涉及白細胞介素-4 (IL-4)及白細胞介素-5 (IL-5)之 分泌及B細胞之活化(產生抗體),可對抗游離的細菌或寄生 蟲。一般認為’過度的IL-4及IL-5之分泌與過敏及發炎反應 有關。 此外,免疫力之提供可透過主動免疫或被動免疫而達成。 主動免疫是指身體接受外來物質(例如,病菌)刺激後,身體 之免疫系統活化,主動產生對抗該外來物質之免疫力。相對 地,被動免疫是指將對抗特定病原之免疫分子(通常是抗體) 導入身體中’身體並未主動產生該等免疫分子。一般而言,主 動免疫需較長時間產生免疫力,但效果持久,而被動免疫可較 201137124 快提供免疫力,但效果不持久。 已有先前技術提出一種作為免疫刺激劑之組合物,1 數種中草藥’可提高U之分泌,但升 6,464,982 ) 〇 ^ 此外,已知雌性禽類經特定病原之致免疫作用後,其產下 之蛋的蛋黃部分具有對抗該特定病狀特紐抗體,從^ 分離出所需的特異性抗體,以被動免疫方式對抗該病原 引起的疾病。相關技術已發展多年,可用於,例如,舒緩沙門 氏菌 pmen.ow 59: 416-20)、輪 138: 143-8)等所引起的腹瀉及縮短其腹濕期間。 專人揭不,以幽門螺旋桿菌(价"⑺免疫母雞, 進而從該母魅下之雜的蛋黃部分,分離出對抗幽門螺旋桿 菌之抗體,該抗體可用於治療幽門螺旋桿菌之感染(― flW Dzag騰"c 卿^;y /麵_/〇肌 9(5): 1061-1066)。201137124 VI. Description of the Invention: [Technical Field] The present invention relates to an immunomodulatory composition which enhances an individual's immune response against a pathogen and reduces an inflammatory response. ~ [Prior Art] The immune system is a defense system used by the body to protect against foreign microorganisms, toxins, cancer cells of its own, or potentially harmful substances such as blood or tissues from others. The immune system can be divided into congenital and acquired immune systems. The innate immune system (also known as the non-specific immune system) serves as the first defense mechanism that provides immediate protection. The relevant members include natural killer cells, macrophages, neutrophils, and eosinophils. The acquired immune system (also known as the specific immune system) is the second defense mechanism that takes time to produce an immune response against a specific antigen, including T cells and B cells. The acquired immune system produces a helper T cell type 1 (Thl) immune response and a helper T cell type 2 (Th2) immune response. The Thl immune response mainly refers to the cell-mediated immune response, which involves the secretion of interleukin-2 (IL-2) and interferon-γ (IFN-γ) and the activation of cytotoxic T lymphocytes (CTLs). Fight against viral infections and cancer cells. The Th2 immune response mainly refers to the humoral immune response, which involves the secretion of interleukin-4 (IL-4) and interleukin-5 (IL-5) and the activation of B cells (antibody production) against free bacteria. Or parasites. It is generally believed that 'excessive secretion of IL-4 and IL-5 is associated with allergic and inflammatory responses. In addition, the provision of immunity can be achieved by active or passive immunization. Active immunity means that the body's immune system is activated after being stimulated by foreign substances (for example, germs), and actively generates immunity against the foreign substance. In contrast, passive immunization refers to the introduction of immune molecules (usually antibodies) against specific pathogens into the body. The body does not actively produce such immune molecules. In general, active immunity takes a long time to produce immunity, but the effect is long-lasting, while passive immunity can provide immunity faster than 201137124, but the effect is not lasting. The prior art has proposed a composition as an immunostimulating agent, and a plurality of Chinese herbal medicines can increase the secretion of U, but rises 6,464,982. 〇^ In addition, it is known that female birds are produced by specific pathogens. The egg yolk portion of the egg has a specific antibody against the specific condition, and the specific antibody required for isolation is isolated from the disease by passive immunization against the pathogen. Related art has been developed for many years and can be used, for example, to relieve diarrhea caused by Salmonella pmen.ow 59: 416-20), round 138: 143-8), and to shorten its abdominal wetness period. Specialized people can not use Helicobacter pylori (price) (7) to immunize hens, and then isolate the anti-Helicobacter pylori antibody from the yolk part of the maternal charm, which can be used to treat Helicobacter pylori infection ( flW Dzag Teng "c Qing ^; y / face _ / diaphragm muscle 9 (5): 1061-1066).

Mar轉dt等人(US 7,355,〇92)揭示一種提供大腸桿菌纖毛抗 原之基因疫苗,並說明該基因疫苗投予母雞後,可收集產下之 雞蛋及進一步從該雞蛋分離出對抗纖毛抗原之抗體,俾於人體 或動物提供被動免疫以對抗腹瀉疾病。 、 然而,目别尚無文獻揭示一雌性禽類經抗原刺激後產下之 禽蛋具有調節個體之免疫功能之功效。 【發明内容】 本案首次揭露一來自經幽門螺旋桿菌致免疫之雌性禽類 產下之蛋的蛋黃產物具有t周節個體之免疫功能之功效,特別是 可提升自然殺手細胞毒殺活性、促進IFN_Yi產生以及抑制 IL-4與IL-5之產生,因而可使個體之免疫反應趨向於Thl免 疫反應’避免Th2發炎反應的發生,有助於對抗外來病原及降 低發炎反應。 因此,在一方面,本發明提供一種免疫調節組合物,其包 201137124 鴨、或鵝。 杈佳者’该雌性禽類為雞、 黃及====疫;=進-步包括桑 黃產物、桑黃及幾丁聚醋之重量比為ϋ周即】組合物所含蛋 品。典型地,本發明之免疫·組合物可作為i添加物或食 本發明之各個具體實例的細 下各個具體實例中的詳 常知心==^^中具有通 ,以下的說明健是 式限制其餘的揭露内容。 用而非以任何方 【實施方式】 在方面本务明長1供一種免疫調節組合物,:a:舍括|主 黃產物係來自經幽門螺旋桿菌、其片段 疫之雌性禽類所產下之蛋。 乃仅4,、且口致免 士 有心明’所有在此處使用的技術性和科學性術扭且 有如f本發明所屬技藝中之通常技術者-般所瞭^音 (ίΓΓ的、「一」乙詞,如未特別指明,^指至^一個 (一個或一個以上)之數量。 質時本免疫-g卩」乙詞’當祕形容—試劑或物 質具有改變或調整至少—種免疫系統之 但不限於’改變或調整免疫系統之成員細胞 或作用刀子(例如,細胞激素及抗體)之數量(或含量/ 或活性。在相關領域中’已發展各種測試方法,以評估一試劑 或物質之免疫調節功能,例如’行政院衛生署公佈的健康 之免疫調節魏評估方法’其包括天赌手活性分析及細胞激 201137124 纽靖功缺财狄狀轉與細節 j文所使用的「蛋黃產物」乙詞是指—分離自 =蛋之蛋黃雜,其可為未經加工者或經加 =產 方式’包括但不限於,冷凍乾燥。 "建加工 本文所使用的「致免疫作用」是指將一試劑或物" 使該個體之免疫反應受到活化,較佳地, 而產生對抗該試劑或物質之特異性免疫反應。 肩體因 根據本發明,可將幽門螺旋桿菌投予^性禽類 疫^ ’然魏鏡等雌性禽類產下的蛋 5致免 冷繼),進而獲1黃=可 虫 產下的蛋之蛋黃部份,可分離出 螺姊滅之特抗體並用以治療幽門螺旋桿菌二幽Η ,明係首次揭示並證實從經由幽門螺旋桿菌致免疫之 S 了之ff獲得的蛋黃產物具有免_節之功效。如下述ί 不,Ϊ較於對照組,服用該等蛋黃產物之小鼠,面臨ίΐ 貝之挑戰,展現增強的Thl S疫反應(IFN之分 ίΓίTh2免疫反應(I1-4 * il-5之分泌™ϋ i 免疫力且可降低發炎反應之產生,其對個^ 章上ϊί ί 免疫雌性禽類之幽門螺旋桿菌可由商 ”適=_菌,經離心後,以超音波震二J離 ^ ’收集上清液’此即為間螺旋桿菌溶胞產物。取用適备之 =螺旋桿菌溶胞產物與佐劑混合,以肌肉注射方式,投I雌 達ΐϊΐ疫作用。在適當時間之後,收集綱性禽類 發:黃部份’進而獲得所述蛋黃產物。根據本 《月進灯致免疫作狀雜禽類,包括但靴卿、鴨及鶴, 201137124 較佳為雞。 上述以幽門螺旋桿菌致免疫雌性禽類、以及後續收 及取得蛋黃部份之相關技術已為此"領▲所孰 ^ (^)〇 經加於騎錢黃絲可進一步 在部分具體實辦’本發明之免疫 ;所紐黃產物餘Μ成為料乾燥黃粉 較佳地,本發明之免疫調節組合物為口服形式。 括桑中’本發明之免疫調節組合物可進-步包 桑黃為-寄生於桑樹的多年生、木層孔菌屬真菌 ’是傳統中藥材,可由商業上獲得。近年ί °»f=九報口 ^曰出桑黃具有抗氧化、抗突變、抗腫瘤活性,以 及保護肝臟的_。 體财性’以 掌上聚幾丁質脫去部份或全部乙酿基之產物’可由商 二,^付取由於破稱具有減重的功,曾經相當流行。除此之 菌的對於脂f傾的影_及增強免疫、抗腫瘤及抗 囷的活性是最受廣泛探討的。 甸夂柷 方此在—特定具體實例中,本發明之免疫調節組合物包括*至 疫之雌經幽門螺旋桿菌、其片段或組合致ί ΐί: ίΐ:ί蛋,以及桑黃與幾丁聚醣,其中所述蛋 再產物、桑頁與幾丁聚醣的重量比約為2 : 2 : 1。 用,ΐίϊίί實射’為縣發日狀倾岭物方便服 护成ΪΪΐ 蛋黃產物可進—頻赫性齡混合調配, 可形成膠囊形式、旋劑形式、丸劑形式、懸浮 液形式、或齡形式。適用於本發明之免疫 ^ 201137124 =成分包括’但不限於’稀釋劑、黏結劑、潤滑劑、抗氧化劑、 著色劑、填充劑、保藏劑及安定劑。 可用的稀釋劑包括羧甲基纖維素鈉、山梨糖醇、滑石、葡 聚糖、乳糖、蔗糖、甘露醇及其類似物。 ^可用的黏結劑包括阿拉伯膠、海藻酸鈉、乙基纖維素、洋 菜、明膠、澱粉、羥基纖維素、羥丙基纖維素及其類似物。 卜可用的潤滑劑包括硬脂酸、硬脂酸弼、硬脂酸鎂、滑石、 氫化油、臘及其類似物。 可用的抗氧化劑包括生育醇、二丁基羥基曱苯、丁基羥基 曱氧苯、抗壞血酸及其類似物。 本發明所屬技術領域具通常知識者可依習知技術及參酌 本案說明書内容翻適當成分概本發狀免賴節組合物。 本發明之免疫調節組合物可直接投予個體,或作為食品添 加物,添加至食品中,或作為食品。 本=明之免疫調節組合物可用於調節個體之免疫反應。更 具體而言,本發明之免疫調節組合物可提升自然殺手細胞毒殺 /舌ί·生、促進IFN-γ之產生以及抑制IL_4與IL_5之產生。因此, 本發明之免疫調節組合物有助於提升個體對抗外來病原之免 ,力且可降低發炎反應之產生,賊個體有相當正面的助益。 本,明之免疫調節組合物可用於正常個體之平日保健或免疫 ^不佳之虛弱個體(例如,癌症或愛滋病患者)之免疫功能 改善。 相心,文所使用之「健」乙詞,包括但狐於,人類及非人 類動物,例如,牛、羊、緒、馬、狗及猶。 以下實例僅作為說明,而非作為本發明之限制。 實例 藥品 卵蛋白(ovalbumin, ova )、肝素(heparin )、刀豆球蛋白a (ConA)、脂多 _ (LPS)、漠化 3_ (4,5_二甲基令坐_2) _2, 5-—苯基四氮唑(MTT)、二甲基亞砜(DMS〇)、弗氏佐劑 201137124 (Freund’s adjuvants)、Hank’s 平衡鹽溶液(HBSS)、Delbecco 改良的 Eagle 培養基(DMEM)、RPMI 1640、台盼蘭(trypan blue)、吐溫-20 (Tween-20)以及牛血清蛋白(BSA)係購自 美國 Sigma-Aldrich 公司。 胎牛血清(FB S )係構自澳洲paa Laboratories GmbH公 司(Pasching,澳洲)。Mar to dt et al. (US 7,355, 〇92) discloses a genetic vaccine for providing E. coli cilia antigens, and demonstrates that after the genomic vaccine is administered to hens, the laid eggs can be collected and further isolated from the eggs to fight against ciliated antigens. The antibody provides passive immunity against diarrheal diseases in humans or animals. However, there is no literature to disclose the effect of a female poultry egg produced by antigen stimulation to regulate the immune function of an individual. SUMMARY OF THE INVENTION The present invention discloses for the first time that an egg yolk product derived from eggs produced by Helicobacter pylori-immunized female birds has the immune function of t-week individuals, in particular, can enhance natural killer cell toxicity and promote IFN_Yi production. Inhibition of IL-4 and IL-5 production, thus allowing the individual's immune response to Thl immune response 'to avoid the occurrence of Th2 inflammatory response, help to combat foreign pathogens and reduce inflammatory response. Thus, in one aspect, the invention provides an immunomodulatory composition comprising 201137124 duck, or goose.杈佳者' The female poultry is chicken, yellow and ==== epidemic; = step-by-step includes the weight ratio of mulberry yellow product, mulberry yellow and chitosan vinegar is the egg contained in the composition. Typically, the immunological composition of the present invention can be used as an i-additive or a detailed description of the specific examples in the specific examples of the present invention, and the following description is intended to limit the rest. The disclosure of the content. Use instead of any side [Embodiment] In the aspect of the present invention, an immunomodulatory composition is provided: a: abbreviated|the main yellow product is derived from a Helicobacter pylori, a female bird thereof egg. It’s only 4, and it’s a singularity. All the technical and scientific techniques used here are as good as those of the ordinary technology in the art of the present invention. "B", if not specified, ^ refers to the number of one (one or more). Qualitative time immunization - g 卩 "B" "describes" - the reagent or substance has changed or adjusted at least - the immune system However, it is not limited to 'changing or adjusting the number (or content/activity) of member cells or knives (eg, cytokines and antibodies) of the immune system. Various test methods have been developed in the related art to evaluate a reagent or substance. The immune regulation function, such as 'the evaluation method of healthy immune regulation Wei published by the Department of Health of the Executive Yuan', including the analysis of the activity of the gambling hand and the cell stimulating 201137124, the yolk product used in the details "B" means - isolated from the egg yolk miscellaneous, which can be unprocessed or added = production mode 'including but not limited to, freeze-drying. By "using a reagent or substance", the immune response of the individual is activated, preferably, to produce a specific immune response against the agent or substance. The shoulder body is capable of administering H. pylori according to the present invention. To the sex poultry epidemic ^ 'Ran Wei Jing and other female poultry eggs 5 to avoid cold), and then get 1 yellow = yolk portion of the egg produced by the worm, can be isolated from the snail and the special antibody In order to treat H. pylori II, the Ming system first revealed and confirmed that the egg yolk product obtained from the ff of Helicobacter pylori-immunized S has a _ _ effect. As shown below, Ϊ No, Ϊ compared with the control group, taking The mice with these egg yolk products face the challenge of ΐ ΐ , , , , , 展现 增强 增强 增强 增强 增强 增强 IFN IFN IFN IFN IFN IFN IFN IFN IFN IFN IFN IFN IFN IFN IFN IFN IFN IFN IFN IFN IFN IFN IFN IFN IFN IFN IFN IFN IFN IFN IFN IFN IFN IFN IFN Helicobacter pylori, which is vaccinated against female cockroaches by the quotient of ^ ί ί 可由 适 _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ Product. Take appropriate = Spirulina solution The cell product is mixed with an adjuvant, and the plague effect is administered by intramuscular injection. After an appropriate time, the embryonic poultry hair is collected: the yellow part is further obtained to obtain the egg yolk product. Complicated poultry, including buttocks, ducks and cranes, 201137124 is preferably chicken. The above-mentioned technology for immunizing female birds with Helicobacter pylori and the subsequent acquisition of the yolk fraction has been done for this. ^ (^) 〇 加 加 骑 骑 加 加 可 可 可 加 加 加 加 加 加 加 加 加 加 加 加 加 加 加 加 加 加 加 加 加 加 加 加 加 加 加 加 加 加 加 加 加 加 加 加 加In the mulberry mulberry, the immunomodulatory composition of the present invention can be further processed into a sapling, and the perennial, Phytophthora fungi, which is parasitic on mulberry trees, is a traditional Chinese medicinal material and is commercially available. In recent years ί °»f=九报口 ^ 桑 桑 具有 has anti-oxidation, anti-mutation, anti-tumor activity, and protect the liver _. It is quite popular to use the chitin to remove some or all of the products of the brewing base. In addition to this, the activity of lipids and the activities of enhancing immunity, anti-tumor and anti-caries are the most widely studied. In a specific embodiment, the immunomodulatory composition of the present invention comprises * to the vaccinated female Helicobacter pylori, a fragment thereof or a combination of ί ΐ ί: ίΐ: ί eggs, and mulberry yellow and chitosan Sugar, wherein the weight ratio of the egg re-product, mulberry to chitosan is about 2:2:1. Use, ΐ ϊ ϊ ϊ 为 为 为 县 县 县 县 县 县 县 县 县 县 县 县 县 县 县 县 县 县 县 县 县 县 县 县 县 县 县 县 县 县 县 县 县 县 县 县 县 县 县 县 县 县 县 县 县 县 县 县 县 县. Immunity suitable for use in the present invention ^ 201137124 = Ingredients include, but are not limited to, diluents, binders, lubricants, antioxidants, colorants, fillers, preservatives, and stabilizers. Useful diluents include sodium carboxymethylcellulose, sorbitol, talc, dextran, lactose, sucrose, mannitol, and the like. Useful binders include gum arabic, sodium alginate, ethyl cellulose, seaweed, gelatin, starch, hydroxycellulose, hydroxypropylcellulose, and the like. Useful lubricants include stearic acid, barium stearate, magnesium stearate, talc, hydrogenated oils, waxes and the like. Useful antioxidants include tocopherols, dibutylhydroxyindole, butyl hydroxy oxybenzene, ascorbic acid, and the like. Those skilled in the art to which the present invention pertains can turn over the appropriate components of the appropriate composition according to the known techniques and the contents of the present specification. The immunomodulatory composition of the present invention can be administered directly to an individual, or as a food additive, added to a food, or as a food. The immunomodulatory composition of the present invention can be used to modulate an individual's immune response. More specifically, the immunomodulatory composition of the present invention enhances natural killer cell killing/tongue production, promotes production of IFN-γ, and inhibits production of IL_4 and IL-5. Therefore, the immunomodulatory composition of the present invention helps to enhance the individual's immunity against foreign pathogens, and can reduce the incidence of inflammatory reactions, and the individual thief has considerable positive benefits. The immunomodulatory composition of the present invention can be used for the improvement of the immune function of a normal individual or a weak individual (for example, a cancer or an AIDS patient). In contrast, the word "jian" used in the text includes but foxes, humans and non-human animals, such as cattle, sheep, ethics, horses, dogs and jealousies. The following examples are illustrative only and not intended to be limiting of the invention. Examples of pharmaceutical egg protein (ovalbumin, ova), heparin (heparin), concanavalin a (ConA), lipopoly (LPS), desertification 3_ (4,5_ dimethyl order sitting_2) _2, 5 - phenyltetrazolium (MTT), dimethyl sulfoxide (DMS 〇), Freund's adjuvant 201137124 (Freund's adjuvants), Hank's balanced salt solution (HBSS), Delbecco's modified Eagle's medium (DMEM), RPMI 1640 Trypan blue, Tween-20, and bovine serum albumin (BSA) were purchased from Sigma-Aldrich, USA. Fetal bovine serum (FB S ) is constructed from Paa Laboratories GmbH, Australia (Pasching, Australia).

DuoSet ELISA發展系統係購自美國r & d系統公司(明 尼阿波里斯市,明尼蘇達州,美國)。 數據呈現及統計The DuoSet ELISA Development System was purchased from the US R & d Systems Corporation (Minneapolis, Minnesota, USA). Data presentation and statistics

一以下實例之實驗結果以平均值±標準誤差(Mean±SD)表 不。以學生t檢驗(Studenfs t-test)進行各組比較,p < 〇.〇5者 代表有顯著差異。 實例1 :幽門螺旋桿菌之製備 幽門螺旋=菌之製備主要依據Shin等人(同上)所揭示 之方法進行。簡言之’將美國菌種保藏中心編號ATCC 435〇4 =幽門螺旋桿菌培養於布氏肉湯(brucdla br〇th ,Difco實驗 二’底特律市’密西根州’美國),其含有5%的胎牛血清及抗 包括2.5 pg/ml之兩性黴素B,1〇 μ§/ιη1之萬古黴素、5 ΪΪ1之三甲鮮氨喷唆;及2.5 IU/ml之多關素Β,均購自 ==na化學公司),培養條件為37。〇、1〇% c〇2及2 ^速度。取出培養的幽門螺旋桿菌,以12,_ χ g離心1〇 音波° f離心後’取得上清液’此為幽門螺 p.干 以一辛可寧酸方法(bicinchoninicacidmethods,The experimental results of the following examples are shown as mean ± standard error (Mean ± SD). Each group was compared by Student's t-test (Studenfs t-test), and p < 〇.〇5 represents a significant difference. Example 1: Preparation of Helicobacter pylori The preparation of pyloric helix = bacteria was mainly carried out according to the method disclosed by Shin et al. (supra). Briefly, 'The American Type Culture Collection No. ATCC 435〇4 = H. pylori cultured in Brucella broth (brucdla br〇th, Difco Experiment 2 'Detroit City 'Michigan' USA), which contains 5% Fetal bovine serum and antibiotics including 2.5 pg/ml of amphotericin B, 1〇μ§/ιη1 of vancomycin, 5 ΪΪ1 of trimethylammonium sneeze; and 2.5 IU/ml of succulent sputum, all purchased from ==na Chemical Company), culture conditions are 37. 〇, 1〇% c〇2 and 2^ speed. Remove the cultured Helicobacter pylori and centrifuge at 12, _ χ g for 1 〇 sonic wave ° f after centrifugation 'to obtain the supernatant' This is the pylorus p. dry with a cinchonnic acid method (bicinchoninic acid method,

Mrce,R0ckford,ΠΙ)測量幽門螺旋桿菌溶胞物之蛋白質濃度。 ㈣2 1_母難之致歧仙及免錄黃乾粉末之⑽ 取刖述實例1之幽門螺旋桿ϋ溶胞物( m u 美國)此合後,以肌肉注射之方式投予母雞 週齡,B_⑽一,-⑸。每-隻母雞:=上 201137124 有4個位置接受注射,每個位置劑量為25〇 μ1。在第—次注射 後,每隔二週,以混合弗氏不完全佐劑之幽門螺旋桿菌溶胞 物進行二次增強反應。在完成最後一次增強反應一個月後, 收集母雞產下的雞蛋,取出蛋黃部份,進行冷凍乾燥,獲得免 疫蛋黃凍乾粉末(下稱「IgY-HP」)。 又 實例3 :小鼠之處理方法 L小鼠之來源及其飼養管理 此處使用之小鼠為6週齡、雌性BALB/c小鼠,其係購自 樂斯科生物科技股份有限公司(BioLASC〇 Taiwan Ca,Ud,Mrce, R0ckford, ΠΙ) measures the protein concentration of Helicobacter pylori lysates. (4) 2 1_Maternal Difficulty and Unaccountable Yellow Dry Powder (10) Take the pyloric helix lysate (mu US) of Example 1 and submit it to the hen by intramuscular injection. B_(10) one, - (5). Per-hen:=Up 201137124 There are 4 positions to receive the injection, each position is 25〇 μ1. After the first injection, a second enhancement reaction was carried out every two weeks with a Helicobacter pylori lysate mixed with Freund's incomplete adjuvant. One month after the last enhancement reaction was completed, the eggs laid by the hens were collected, and the yolk portions were taken out and lyophilized to obtain an lyophilized powder of yolk (hereinafter referred to as "IgY-HP"). Further Example 3: Treatment of mice L-source of mouse and its feeding management The mice used herein were 6-week-old, female BALB/c mice, which were purchased from Lesco Biotech Co., Ltd. (BioLASC). 〇Taiwan Ca, Ud,

Taipei,Taiwan)。實驗小鼠之飼養管理經新竹市食品工^發展’ 研究所之動物實驗管理小組審核通過。簡言之,小鼠自^ 觀察兩週,表現不正常情形(如畏光、脫水等)或實驗 落在平均體重±2標準差以外者,均淘汰不用。小 美國^EPCO公司(Warrensburg, ΝΥ )實驗動物專用木屑墊料, 經,菌後使用,每週更換2次。實驗飼料則是美國purina公司 之實驗氛專關料PMI篇。飼養環境為23±2t:的溫度、5〇 ±10 %的相對溼度以及12小時光照與黑暗交替。 2.小鼠之餵食實驗 將小鼠隨機分成二組,每組隻,一組為〗yep實 一組為水,組。觸砂HP實敝之小鼠取約 ί 於約G·2 ml的去離子水,形成砂》懸浮液, 母日以胃Ί* 口服給予該懸浮液,連續十週(從6週齡至16週 ,),=針對水賴組之小鼠,則是每日給料量之去離子水。 3·小鼠之致免疫作用實驗 =小乳亦在#食期間接* Gva致免疫作用。詳言之。 ^ 7 純食實驗時,先由尾部採血,其後分抓 你及13週齡時’進行3次致免疫侧,其中以〇、 if氏佐劑混合後’以皮下注射投予小鼠,勒 没乍用,以及以ova作為抗原與不完全弗氏佐劑2 201137124 3合主射投予小5,進行第2次及第3次致免疫作用。 射二積i i〇°〇vm^i2 Mg、1〇吨及1〇即,每次注 射體,為_μΙ。母次致免疫作用後定期自尾部採血。 小鼠16週齡完成最後一次餵食實 後,全身噴酒精消毒,移至生物安全操,I:Taipei, Taiwan). The feeding management of experimental mice was approved by the Animal Experimental Management Team of the Research Institute of Food Industry in Hsinchu City. In short, the mice were observed for two weeks, and the abnormalities (such as photophobia, dehydration, etc.) or the experiments falling outside the mean body weight ± 2 standard deviation were eliminated. Small United States ^EPCO company (Warrensburg, ΝΥ) experimental animal-specific wood filings, after the use of bacteria, replaced twice a week. The experimental feed is the PMI article of the experimental atmosphere of the American Purina Company. The breeding environment was 23 ± 2 t: temperature, 5 〇 ± 10% relative humidity and 12 hours of light and dark alternating. 2. Feeding experiment of mice The mice were randomly divided into two groups, each group was only one group, and one group was defined as yep. The mice exposed to the HP sputum were taken from about 2.8 ml of deionized water to form a sand suspension, and the suspension was orally administered to the mother for 10 weeks (from 6 weeks to 16 weeks). Week,), = for the mice in the water-receiving group, the daily feeding amount of deionized water. 3. Immunization experiment in mice = small milk also received * Gva to induce immunity during #食. In detail. ^ 7 In the pure food experiment, the blood is collected from the tail first, and then you are arrested at 13 weeks of age and '3 times of immunogenic side, which is mixed with if, if, adjuvant, and administered to mice by subcutaneous injection. No use, and ova as the antigen and incomplete Freund's adjuvant 2 201137124 3 combined with the main shot to the small 5, the second and third immunogenic effects. The second product i i〇°〇vm^i2 Mg, 1 ton and 1 〇, each time the injection body is _μΙ. Blood is collected from the tail periodically after maternal immunogenicity. After the mice were finished at the age of 16 weeks, the whole body was sprayed with alcohol and moved to biosafety operation. I:

5採取脾臟的步驟。表1顯示所述之小鼠處理進订 泰1:小鼠虚㈣叙 J 實驗 小鼠5 steps to take the spleen. Table 1 shows the treatment of the mouse in the preparation of Tai 1: mouse virtual (four) Syrian J experiment mice

時間 週齡Time

適應環境 秤重分籠,採血,開始灌Adapt to the environment, weigh the cage, collect blood, start irrigation

1 7 2 8 3 9 4 10 5 11 6 12 7 13 8 14 9 15 10 16 食 第1次致免疫作用 採血 第2次致免疫作用 採血 第3次致免疫作用1 7 2 8 3 9 4 10 5 11 6 12 7 13 8 14 9 15 10 16 Food 1st immunogenicity Blood collection 2nd immunogenicity Blood collection 3rd immunogenicity

實例4:小鼠之髏重分# 在如述十週之餘食期pq 並觀 察小鼠生長狀況。表2 g ’Λ週定時測量小鼠之體重 表2:小鼠體重測量結果、、氣體重測量結果。 201137124 實驗 時間 (週) 〇^ 1 2 3 4Example 4: Mice's sputum re-pointing # The pq was observed for ten weeks as described and the growth of the mice was observed. Table 2 g's weekly body weight measurement of mouse body Table 2: mouse body weight measurement results, gas weight measurement results. 201137124 Experiment Time (Week) 〇^ 1 2 3 4

水對照組 (n=12)Water control group (n=12)

IgY-HP實驗組 (n=12) 6 7 8 9 10 11 12 13 14 15 16 20.9±1.0 21.3±0.7 19.6±0.6 21.2±1.〇 22.2±0.9 23.4±0.7 24.7±0.8 25.1±0.8 25.2±0.7 25.8±1.2 h結果以平触 2. *表示與水龍組間有顯著差異(p<0.05)重早位為克(gm> 卞表2所不’在第6至8週期間 體重出現低於水對照組者的現象,但後續第9 /=== Ig爾實驗組與水對照組之小鼠體$至=週= 性,與餵食成份無關。 v 5 6 7 8 9 10 20.9±0.7 21.4±〇.3 19.8±0.6 21.3±〇.722.2±〇.6 23·1±〇.7 23.7土 0.6* 24.1±〇.6* 24.8±0.7* 25.1±〇.6 25.3 士 0.6 實例5 :非特異性抗逋總董分析 。將前述完成十週餵食實驗之小氣犧牲後取得之全血,保存 於4 C ’ 以抗體檢測試劑(Mouse Ig ELISA Quantitation Kit, Bethy丨公司,蒙哥馬利市,德州’美國)’依說明方式使用三 明治型酵素連結免疫分析法(sandwich enzyme-linked immunosorbent assay, sandwich-ELISA)測定血液所含 IgG 抗體 之總量。表3顯示非特異性lgG抗體總量之測量結果。 表3 :非特異性抗體總量測量結果 201137124IgY-HP experimental group (n=12) 6 7 8 9 10 11 12 13 14 15 16 20.9±1.0 21.3±0.7 19.6±0.6 21.2±1.〇22.2±0.9 23.4±0.7 24.7±0.8 25.1±0.8 25.2±0.7 25.8±1.2 h results in a flat touch 2. * indicates a significant difference with the water dragon group (p < 0.05) and the early morning position is gram (gm > 卞 Table 2 does not 'the weight appears below the water during the 6th to 8th week The phenomenon of the control group, but the subsequent 9 /=== Iger experimental group and the water control group of the mouse body $ to = week = sex, regardless of the feeding composition. v 5 6 7 8 9 10 20.9 ± 0.7 21.4 ± 〇.3 19.8±0.6 21.3±〇.722.2±〇.6 23·1±〇.7 23.7 soil 0.6* 24.1±〇.6* 24.8±0.7* 25.1±〇.6 25.3 ± 0.6 Example 5: Non-specific Analysis of the anti-tuberculosis director. The whole blood obtained after the completion of the ten-week feeding experiment was saved in 4 C ' antibody detection reagent (Mouse Ig ELISA Quantitation Kit, Bethy丨, Montgomery, Texas 'USA)' The total amount of IgG antibodies contained in the blood was determined by sandwich enzyme-linked immunosorbent assay ( sandwich-ELISA) according to the instructions. Table 3 shows the non- The measurement results of the total amount of lgG antibodies heterosexual Table 3: nonspecific antibody measurement result of the total 201 137 124

IgG 抗體總量 (Hg/mL ) 水對照 、组 (n=9) 致免疫作用前 第1次致免疫作用 第2次致免疫作用 第3次致免疫作用 57士 12 120±14 344±99 830±246Total IgG antibody (Hg/mL) Water control, group (n=9) The first immunization before immunization The second immunization The third immunization 57 Shi 12 120±14 344±99 830 ±246

IgY-HP實驗 組 __(η=10) 51士8 133±26 533±173* 1010±317 1·結果以平均值+標準差(mean+ SD)表示 2. *表示與水對照組間有顯著差異。 '、 量提取可促使小鼠血液收抗體總 j升(第2次致免疫作用後),到第3次致免疫作 视 J驗組之IgG抗體總量平均值仍高於水對照組者(上二者間 未顯不統計上的差異,推測是過早激活所致)。 實例6 ·非特異性自然殺手細胞畚殺活性之分析 s Λίίί成十舰食實驗之小_牲後取出之脾臟,置於 m巾。湘針筒推進||之平尾端她壓住脾臟並將之 f碎总直到顏色變成白色’表示結締組織間的脾臟細胞已游離 ,培養液巾。雜,將含有義細胞之培養歧取至離心管, 靜置5至10分鐘,使得結締組織或大顆粒碎屑沈澱至下方。 ,後,將上方的細胞懸浮液吸取至另一離心管中,以25〇 xg 離心5分鐘。丢棄上清液後,輕拍管壁,使管底之細胞均句散 開。加入5 ml冰冷的ACK紅血球瓦解緩衝液,與管中的細胞 均勻混^ ’作用1分鐘後,加入5 ml已回溫並含血清之培養 液。接著再以250 xg離心5分鐘,丟棄上清液後,以1〇 ml 之HBSS緩衝液清洗2次’將細胞懸浮於1〇 ml培養基中。以 台盼蘭染色計算細胞懸浮液之濃度。 利用細胞毒性分析套組(LIVE/DEAD cell-mediated cytotoxicity kit ’美國分子探針公司,尤金市,美國),檢測小 201137124 鼠脾臟細胞中自然殺手細胞毒殺活性。簡言之’先以染劑 DIOC18標幟自然殺手細胞之標的細胞Ya〇l (37〇C、5% C02 培養箱内’作用16小時),然後將脾臟細胞與標的細胞(E/T) 以1 : 100或1 : 200之比例混合,於37°C、5% C〇2培養箱内, 作用4小時。陰性對照組則是以rpmi 1640培養液(含1〇%胎 牛血清)取代脾臟細胞與標的細胞混合。以流式細胞儀分析細 胞數量。 自然殺手細胞毒殺活性(%)之計算方式為「實驗組之標 的細胞死亡率一陰性對照組之標的細胞死亡率」。表4顯示自 然殺手細胞毒殺活性之分析結果。 自然殺手細胞活性 水對照組 IgY-HP實驗組 (%) (n=10) (n=10) 自然殺手細胞活性f〇/n) E/T=100:l 35.2 ±3.4 39.0 士 5.0 E/T =200:1 39.9 ±3.1 45.8 ±5.3* 1. 結果以平均值+標準差(mean + SD)表示。 2. *表示與水對照組間有顯著差異。 表4 :自然殺手細胞活性分妍钴吴 φ 如表4所示’ lgY_HP實驗組之自然殺手細胞活性明顯地 較水對照組者為高(p<〇.〇5),顯示IgY_HP具有促進自然殺手 細胞毒殺活性的作用。 實例7 :非特異性細胞激素分泌分析 在24孔培養盤中,分別加入培養液(對照組)、含ConA (最終濃度」或LPS (最終濃度:1〇μδ/ιη1)之培養 液6’並加入實例4之脾臟細胞懸浮液,使每孔細胞總數為〇 4 X /10個細胞。於37°c、5% 0)2培養箱内,培養24及48小時 ,收集細胞培養上清液。使用細胞激素檢驗套組 ELISADevel〇pmentSystem,美國 R&D 系統公司明 里斯市’明尼蘇達州’美國),以三明治型酵素連結免疫分析 14 201137124 法(sandwich enzyme-linked immunosorbent assay, sandwich-ELISA),測量細胞培養上清液中非特異性細胞激素’ IL-2、IFN-γ、IL-4及IL-5之含量。表5顯示非特異性細胞激 素之測量結果。 表5 .非特異性細胞激素之測量結果 水對照組 IgY-HP實驗組 -----(n=10) — (n=l〇) IL-2 ( pg/mL ) 培養液 17±99 ConA 9423±2463 LPS 19士 6 IFN-γ ( pg/mL ) 培養液 〇±〇 ConA 3013±814 LPS 960±529 IL-4 ( pg/mL ) 培養液 0±0 ConA 337±189 LPS 12±2 IL-5 ( pg/mL ) υ±υIgY-HP experimental group __(η=10) 51±8 133±26 533±173* 1010±317 1·Results are expressed as mean + standard deviation (mean+ SD) 2. * indicates significant difference with water control group difference. ', the amount of extraction can promote the total amount of antibody in the blood of mice (after the second immunization), the average of the total amount of IgG antibodies in the third immunization test group is still higher than the water control group ( There is no statistical difference between the two, which is presumed to be caused by premature activation). Example 6 · Analysis of the killing activity of non-specific natural killer cells s Λίίί into the small ship food experiment _ spleen taken after the sacrifice, placed in m towel. Xiang syringe advancement||At the end of the flat, she pressed the spleen and shattered it until the color turned white', indicating that the spleen cells between the connective tissues were free, and the liquid towel was cultured. Miscellaneous, the culture containing the sense cells is taken to a centrifuge tube and allowed to stand for 5 to 10 minutes, so that connective tissue or large particle debris is precipitated below. Thereafter, the upper cell suspension was pipetted into another centrifuge tube and centrifuged at 25 Torr xg for 5 minutes. After discarding the supernatant, pat the wall to spread the cells at the bottom of the tube. Add 5 ml of ice-cold ACK red blood cell disruption buffer, and evenly mix with the cells in the tube for 1 minute, then add 5 ml of the warmed and serum-containing medium. Then, the cells were centrifuged at 250 xg for 5 minutes, and the supernatant was discarded, and then washed twice with 1 〇 ml of HBSS buffer. The cells were suspended in 1 ml of the medium. The concentration of the cell suspension was calculated by trypan blue staining. The natural killer cell cytotoxic activity in the spleen cells of the small 201137124 mouse was examined using a cytotoxicity assay kit (LIVE/DEAD cell-mediated cytotoxicity kit ‘American Molecular Probes Inc., Eugene, USA). In short, 'first use the dye DIOC18 marker natural killer cell target cell Ya〇l (37〇C, 5% C02 incubator for 16 hours), then spleen cells and target cells (E/T) 1 : 100 or 1: 200 ratio mixing, in a 37 ° C, 5% C 〇 2 incubator, for 4 hours. In the negative control group, spleen cells were mixed with the target cells in rpmi 1640 medium (containing 1% fetal bovine serum). The number of cells was analyzed by flow cytometry. The natural killer cytotoxic activity (%) was calculated as "the target cell death rate of the experimental group and the target cell death rate of the negative control group". Table 4 shows the results of analysis of natural killer cytotoxic activity. Natural killer cell active water control group IgY-HP experimental group (%) (n=10) (n=10) natural killer cell activity f〇/n) E/T=100:l 35.2 ±3.4 39.0 ±5.0 E/T =200:1 39.9 ±3.1 45.8 ±5.3* 1. The results are expressed as mean + standard deviation (mean + SD). 2. * indicates a significant difference from the water control group. Table 4: Natural killer cell activity, 妍Cobalt Wu φ As shown in Table 4, the natural killer cell activity of the lgY_HP experimental group was significantly higher than that of the water control group (p<〇.〇5), indicating that IgY_HP has a natural killer. The role of cytotoxic activity. Example 7: Non-specific cytokine secretion assay In a 24-well culture dish, a culture solution (control group), a culture solution containing ConA (final concentration) or LPS (final concentration: 1 〇μδ/ιη1) was added, respectively. The spleen cell suspension of Example 4 was added, and the total number of cells per well was 〇4×10 cells. The cells were cultured for 24 and 48 hours in a 37 ° C, 5% 0) 2 incubator, and the cell culture supernatant was collected. Using the cytokine test kit ELISA Devel〇pmentSystem, USA R&D Systems, Minnesota, 'Minnesota' USA, USA, sandwich enzyme-linked immunosorbent assay, sandwich-ELISA, measurement The content of non-specific cytokines 'IL-2, IFN-γ, IL-4 and IL-5 in the cell culture supernatant. Table 5 shows the measurement results of non-specific cytokines. Table 5. Measurement of non-specific cytokines Water control group IgY-HP experimental group-----(n=10) - (n=l〇) IL-2 (pg/mL) Culture medium 17±99 ConA 9423±2463 LPS 19±6 IFN-γ (pg/mL) Culture medium 〇±〇ConA 3013±814 LPS 960±529 IL-4 (pg/mL) Culture medium 0±0 ConA 337±189 LPS 12±2 IL -5 ( pg/mL ) υ±υ

13±7 10225±2099 18 ±3 0.37±1.18 3549±1213 1513±658 〇±l 349±153 9±2*13±7 10225±2099 18 ±3 0.37±1.18 3549±1213 1513±658 〇±l 349±153 9±2*

埒蚕液 ConA LPS υ±υ 260±93* 26±7 470±272 -----25±5 L結果以平均值+標準差(mean + SD)表示„ 2. *表示與水對照組間有顯著差異。 、 胎备5/斤不’與水對照組相較,IgY4iP實驗組之Th2細 有抑制Ϊ分泌量明顯較低(P<〇.〇5);顯示1gY具 虿抑制Th2免疫反應的作用。 實例8:特異性細胞激素分析 15 201137124 以前述實例5之相同方式進行特異 言之’在24孔培養盤中’分別加入培養二。簡 (最終漢度為100 pg/ml)之培養液,並加入$^^)或含〇va 胞懸浮液,使每孔細胞總數為〇·4 x 1〇6個έ 』4之脾臟細 〇)2培養納,培養24及48㈣後物、二 用前述細胞激素檢驗套組,測量細胞培養 細胞激素IL-2、IFN-γ、IL-4及IL-5之人旦狀T 特異性 細胞激素之測量結果。 3 s °表6顯示特異性Tussah ConA LPS υ±υ 260±93* 26±7 470±272 -----25±5 L The result is expressed as mean + standard deviation (mean + SD) „ 2. * indicates between the water control group and the water control group There was a significant difference., Fetal preparation 5 / kg not 'Compared with the water control group, IgY4iP experimental group of Th2 fine inhibition of sputum secretion is significantly lower (P < 〇. 〇 5); shows that 1gY has 虿 inhibition of Th2 immune response Example 8: Specific cytokine analysis 15 201137124 In the same manner as in the above Example 5, the specific 'in a 24-well culture dish' was separately added to the culture 2. The simple (final Han degree was 100 pg/ml) culture. Liquid, and add $^^) or 〇va cell suspension, so that the total number of cells per well is 〇·4 x 1〇6 έ 』 4 spleen fine 〇 2 培养 2 2 2 2 培养 , , , , , , , , , , , , , , , , , Using the aforementioned cytokine test kit, the measurement results of human dendritic T-specific cytokines of cell culture cytokines IL-2, IFN-γ, IL-4 and IL-5 were measured. 3 s ° Table 6 shows specificity

表示 表6 :特異性細胞激素之測量結果 水對照組 50±12 535±19〇 19±6 169± 86 IL-2 ( pg/mL ) IFN-γ (pg/mL) IL-4 ( pg/mL ) IL-5 ( pg/mL) _____ L結果以平均值+標準差(mean+ ; 2.*表示與水對照組間有顯著差異- 的分^表IgY:HP 一方面可抑制ova特異性IL_4及1L-5 (P<〇〇5、二可促使0化特異性IFN_丫的分泌顯著增加 =IgY_HP可促進特異性™細胞激素的分泌, 降低特異性加細胞激素的分泌。 實例自%1ΪΤϋ合粉末轉雜—激素分析 末,盥實:,丨技股份有限公司購得桑黃及幾丁⑽ 製得斤仔之IgY_HP混合’重量比為40%、40%及20%, 為〇.48g-)。組合粉末,裝載於膠囊中(每一膠囊内容物重量 機分實,的方式’進行小鼠飯食。簡言之,將小鼠隨 組為8至12隻,—組為齡水的對照組,另一 ’迷gY-HP組合粉末的實驗組。以7〇kg的成人而 16 201137124 言,作為一般保健用途之建議量為每日服用2顆膠Indicates Table 6: Measurement of specific cytokines Water control group 50±12 535±19〇19±6 169±86 IL-2 (pg/mL) IFN-γ (pg/mL) IL-4 (pg/mL) IL-5 (pg/mL) _____ L results in mean + standard deviation (mean + ; 2. * indicates a significant difference between the water control group - the table IgY: HP on the one hand can inhibit ova-specific IL_4 and 1L-5 (P < 〇〇 5, 2 can promote the secretion of 0-specific IFN_丫 significantly increased = IgY_HP can promote the secretion of specific TM cytokines, reduce the secretion of specific plus cytokines. Examples from %1 Powder conversion - hormone analysis, tamping:, 丨 股份有限公司 购 购 购 购 购 购 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 I I I I I I I I I I I Combine the powder and load it into the capsule (the weight of each capsule is divided into the actual way, the mouse meal is carried out. In short, the mice are 8 to 12 with the group, the group is the water-based control) Group, another experimental group of 'gY-HP combination powder. With 7 〇 kg of adults and 16 201137124 words, as a general health use, the recommended amount is 2 capsules per day.

膠囊)’換算為小鼠(體重20g)服用劑量為約2 j W 針對實驗組:Μ、氣,取前述劑量之Ι§ΥΉρ組合粉= ml的去離子水,形成免疫調節懸浮液,每日以 該懸浮液’連數十週(從6週齡至16週齡);而^ 予 之小鼠’财每日給料量的去離子水。前述小 的方式在餵食期間接受ova致免疫作用。 、實例3 依前述實例8的方式進行特異性細胞激素 於水對照組之細胞激素上升或下降百分比,計 、卞^較 組之細胞激素糧數健水對驗之細麵 (實驗 值/水對照組之細胞激素測量數值)乘以百分之百里$值之差 結果。 。表7顯示 ^L:igY-HP組合粉末之特異性細胞激音公姑 越越IMil缝趟照組) IL-2 ( pg/mL ) IFN-γ (pg/mL) IL-4 (pg/mL) 上升12% 上升40%, 下降68%; 下降59%51 • ' —---- 一 IL-5 (pg/mL)__ *表示與水對照組間有顯著差異。 ——一 另各別進行桑黃及幾丁聚醣的細胞激素分 丨相較於水對照組之細胞激素上升或下降百:比 計算; 結果。 兔jj桑黃及幾丁聚醣之細胞激音公奴 細胞激素變化 IFN-γ (pg/mL)上升 38%* 節 !L-4 (pg/mL) 下降 1〇% 下降12% 201137124 —ikLJpg/mL) 仙 NO,示^^行測試: -----1降23〇/〇 *表示與水對照組間有顯著差異。 2 ’並降低贿性™細胞激素的分匕其功ίΪ 於桑黃或幾丁聚醣單獨時的效果。 錢 =,本發明之IgY_HP證實具提升自然殺手細胞毒殺活 性、如尚IFN-γ的分泌及抑制IL_4及IL_5分泌之功效;且合 併桑黃及幾丁聚醣後’效果優於單桑黃或幾丁聚醣單獨時的效 果。本發明之免疫調節組合物係首次提出,且經證實可促進個 體之免疫反應趨向於Thl免疫反應,避免Th2發炎反應的發 生,對於對抗外來病原及降低發炎反應有相當的助益。Capsules 'converted to mice (body weight 20g) dose is about 2 j W for the experimental group: sputum, gas, take the above dose of Ι ΥΉ ΥΉ ρ combination powder = ml of deionized water to form an immunomodulatory suspension, daily The suspension was 'for several tens of weeks (from 6 weeks to 16 weeks of age); and the mouse was given a daily dose of deionized water. The aforementioned small approach accepts ova immunogenicity during feeding. Example 3 According to the method of the above Example 8, the percentage of the cytokine of the specific cytokine in the water control group was increased or decreased, and the cytokine of the 卞^ group was compared with the healthy surface of the Jianshui test (experimental value/water control) The cytokine measurement value of the group is multiplied by the difference between the value of the hundredth of a hundred percent. . Table 7 shows that the specific cell cytokine of the igY-HP combination powder is more than the IMil suture group) IL-2 (pg/mL) IFN-γ (pg/mL) IL-4 (pg/mL) Increased by 12%, increased by 40%, decreased by 68%; decreased by 59%51 • '----- One IL-5 (pg/mL)__ * indicates a significant difference from the water control group. - A separate cytokine fraction of mulberry yellow and chitosan compared to the cytokine of the water control group increased or decreased by 100: ratio; Cytokine cytokine changes in rabbit jj mulberry and chitosan increased IFN-γ (pg/mL) by 38%* knot! L-4 (pg/mL) decreased by 1〇% decreased by 12% 201137124 —ikLJpg /mL) Xian NO, showing ^^ line test: -----1 drop 23〇 / 〇 * indicates a significant difference between the water control group and the water control group. 2 ‘and reduce the briberyTM cytokine's bifurcation. The effect of mulberry yellow or chitosan alone. Money =, the IgY_HP of the present invention proves to enhance the natural killer cell toxicity, such as the secretion of IFN-γ and inhibit the secretion of IL_4 and IL_5; and the effect of combining mulberry yellow and chitosan is better than single mulberry yellow or The effect of chitosan alone. The immunomodulatory composition of the present invention was first proposed and has been shown to promote the immune response of individuals to the Th1 immune response, avoiding the occurrence of Th2 inflammatory response, and is quite beneficial for combating foreign pathogens and reducing inflammatory response.

Claims (1)

201137124 七、申請專利範圍: i —種免疫調節組合物,其包括蛋黃產物,該蛋黃產物係來 =門螺旋桿菌(极砂/w>/)、其片段或組免疫之 雌性禽類所產下之蛋。 4·、如申请專利範圍第1項之組合物,其中該禽類為雞、鴨、 或鶴。 3.如申請專利範圍第丨項之組合物,其中該蛋黃產物為冷凍 乾燥之粉末。201137124 VII. Patent application scope: i - an immunomodulatory composition comprising an egg yolk product, which is produced by a female bird of the group: Helicobacter pylori (polar sand/w>/), a fragment thereof or a group immunized egg. 4. The composition of claim 1, wherein the bird is a chicken, a duck, or a crane. 3. The composition of claim 3, wherein the egg yolk product is a freeze-dried powder. 4上如申請專利範圍第1項之組合物,其呈膠囊形式、錠劑形 式、銳劑形式、丸劑形式、懸浮液形式、或顆粒形式。 5. 如申請專利範圍第4項之組合物,其中該蛋黃產物為冷凍 乾燥之粉末,併入該膠囊中。 6. 如申請專利範圍第1項之組合物,其係口服形式。 7. 如申請專利範圍第1項之組合物,其中該個體為人類。 8. 如申請專利範圍第1項之組合物’其進一步包括桑黃及幾 丁聚醣。 、 9. 如申請專利範圍第1項之組合物,其中該蛋黃產物、 及焱丁聚醣之重量比為約2:2:1。 、 Ασ 10.如申請專利範圍第1至9項中任一項之組合物,其可作為 艮品添加物或食品。 、 ‘· 19 201137124 四、指定代表圖: (一) 本案指定代表圖為:第( )圖。 (二) 本代表圖之元件符號簡單說明: (無)The composition of claim 1, which is in the form of a capsule, a tablet, a sharp form, a pill form, a suspension form, or a granule form. 5. The composition of claim 4, wherein the egg yolk product is a freeze-dried powder incorporated into the capsule. 6. The composition of claim 1, which is in oral form. 7. The composition of claim 1, wherein the individual is a human. 8. The composition as claimed in claim 1 which further comprises mulberry yellow and chitosan. 9. The composition of claim 1, wherein the weight ratio of the egg yolk product to the chitosan is about 2:2:1. The composition of any one of claims 1 to 9 which can be used as a counterfeit additive or food. ‘· 19 201137124 IV. Designated representative map: (1) The representative representative of the case is: ( ). (2) A brief description of the symbol of the representative figure: (none) 五、本案若有化學式時,請揭示最能顯示發明特徵的化學式: (無)5. If there is a chemical formula in this case, please reveal the chemical formula that best shows the characteristics of the invention: (none) 22
TW099113813A 2010-04-30 2010-04-30 Immunomodulatory compositions TWI490336B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
TW099113813A TWI490336B (en) 2010-04-30 2010-04-30 Immunomodulatory compositions

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TW099113813A TWI490336B (en) 2010-04-30 2010-04-30 Immunomodulatory compositions

Publications (2)

Publication Number Publication Date
TW201137124A true TW201137124A (en) 2011-11-01
TWI490336B TWI490336B (en) 2015-07-01

Family

ID=46759369

Family Applications (1)

Application Number Title Priority Date Filing Date
TW099113813A TWI490336B (en) 2010-04-30 2010-04-30 Immunomodulatory compositions

Country Status (1)

Country Link
TW (1) TWI490336B (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1273193C (en) * 2004-12-16 2006-09-06 上海交通大学 Method for preparing biologics of yolk antibody for anti Helicobacter Pylori

Also Published As

Publication number Publication date
TWI490336B (en) 2015-07-01

Similar Documents

Publication Publication Date Title
Sander et al. Promising plant-derived adjuvants in the development of coccidial vaccines
Arendt et al. Interleukin-10 neutralizing antibody for detection of intestinal luminal levels and as a dietary additive in Eimeria challenged broiler chicks
Lee et al. Effects of dietary supplementation with phytonutrients on vaccine-stimulated immunity against infection with Eimeria tenella
Lee et al. Induction of passive immunity in broiler chickens against Eimeria acervulina by hyperimmune egg yolk immunoglobulin Y
Huber et al. Th1-orientated immunological properties of the bacterial extract OM-85-BV
Lee et al. Protective effect of hyperimmune egg yolk IgY antibodies against Eimeria tenella and Eimeria maxima infections
Roozbehani et al. Characterization of a multi-epitope peptide with selective MHC-binding capabilities encapsulated in PLGA nanoparticles as a novel vaccine candidate against Toxoplasma gondii infection
CA2884092C (en) Inf.alpha.14 combinations for treating autoimmune diseases, inflammatory disorders and allergies
KR101729547B1 (en) Usage of compounds containing tryptophanyl-tRNA synthetase as a Vaccine adjuvant
WO2015136287A2 (en) Compositions and methods relating to the treatment of diseases
Barbour et al. A review of approaches targeting the replacement of coccidiostat application in poultry production
Thompson Immunology: improvement of innate and adaptive immunity
CA2608630C (en) Polysaccharide extract of dendrobii herba and use thereof for treating autoimmune uveitis
JP6509833B2 (en) Mammalian milk osteopontin for enhancing immune responsiveness
Yu et al. A spent hen muscle protein hydrolysate: a potential IL-10 stimulator in a murine model
Xu et al. Effect of dietary bovine colostrum on the responses of immune cells to stimulation with bacterial lipopolysaccharide
Pomorska-Mól et al. The effect of doxycycline treatment on the postvaccinal immune response in pigs
Yektaeian et al. Genetic immunization against toxoplasmosis: A review article
Ren et al. Dietary supplementation of sulfur amino acids improves intestinal immunity to Eimeria in broilers treated with anti-interleukin-10 antibody
US8715671B2 (en) Compositions and methods for modulating immune response
TW201137124A (en) Immunomodulatory compositions
EP4178597A2 (en) Probiotics for use in the prevention or treatment of illness and/or symptoms associated with coronaviruses
Pan et al. Lactobacillus plantarum surface-displayed Eimeria tenella profilin antigens with FliC flagellin elicit protection against coccidiosis in chickens
JP2002529420A (en) Compositions and methods for increasing weight gain and food efficiency
WO2023032008A1 (en) Immunostimulatory formulation, and cosmetic, food, feed additive, and quasi-drug containing said immunostimulatory formulation